Sunshine Heart to Release First Quarter 2015 Results on May 5, 2015
April 28 2015 - 5:30AM
Sunshine Heart, Inc. (Nasdaq:SSH) today announced that its first
quarter 2015 results will be released on Tuesday, May 5, 2015,
before the open of the stock market. The company will host a
conference call and webcast at 9:00 AM ET that morning, during
which management will discuss the company's financial results and
provide a general business overview.
To access the live webcast, please visit the Investors page of
the Sunshine Heart website at http://ir.sunshineheart.com.
Alternatively, you may access the live conference call by dialing
(877) 303-9826 (U.S.) or (224) 357-2194 (international) and using
conference ID 33142990. An audio archive of the webcast will be
available following the call at http://ir.sunshineheart.com.
About the C-Pulse® Heart Assist System
The C-Pulse Heart Assist System, or C-Pulse System, an
investigational device in the United States, Canada and countries
that do not recognize the CE mark approval, utilizes the scientific
principles of intra-aortic balloon counter-pulsation applied in an
extra-aortic approach to assist the left ventricle by reducing the
workload required to pump blood throughout the body, while
increasing blood flow to the coronary arteries. Combined, these
potential benefits may help sustain the patient's current condition
or, in some cases, reverse the heart failure process, thereby
potentially preventing the need for later-stage heart failure
devices, such as left ventricular assist devices (LVADs),
artificial hearts or transplants. It may also provide relief from
the symptoms of Class III and ambulatory Class IV heart failure and
improve quality of life and cardiac function. Based on the results
from our feasibility study, we also believe that some patients
treated with our C-Pulse System may be able to stop using the
device due to sustained improvement in their conditions as a result
of the therapy. Caution: Investigational device, limited by Federal
(or United States) Law to Investigational use. About
Sunshine® Heart Sunshine Heart, Inc. (Nasdaq:SSH) is
an early-stage medical device company focused on developing,
manufacturing and commercializing the C-Pulse System for treatment
of Class III and ambulatory Class IV heart failure. Sunshine Heart
has completed an approved U.S. Food and Drug Administration (FDA)
feasibility clinical study of the C-Pulse System and presented the
results in November 2011. In March 2012, the FDA notified the
Company that it could move forward with an investigational device
exemption (IDE) application. Sunshine Heart received unconditional
approval from the FDA in November 2012 to initiate its pivotal
study. In July 2012, Sunshine Heart received CE Mark approval for
its C-Pulse System in Europe. Sunshine Heart is a Delaware
corporation headquartered in Minneapolis with wholly owned
subsidiaries in Australia and Ireland. The Company has been listed
on the NASDAQ Capital Market since February 2012.
CONTACT: For further information, please contact:
Investor:
Candice Knoll
Blueprint Life Science Group
T: +1-415-375-3340 Ext. 105
Claudia Drayton
Chief Financial Officer
Sunshine Heart, Inc.
T: +1-952-345-4200
Media:
David Schull
Russo Partners
T: +1-212-845-4271
Christopher Hippolyte
Russo Partners
T: + 1-646-942-5634
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Aug 2024 to Sep 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Sep 2023 to Sep 2024